Screener
ADMA Biologics ADMA Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of long-term debt | 3,750 | 2,813 |
| Current portion of lease obligations | 1,178 | 1,096 |
| Liabilities held for sale | - | 2,647 |
| Total current liabilities | 75,757 | 69,541 |
| Long-term debt | 192,839 | 69,330 |
| Deferred revenue, net of current portion | 1,334 | 1,405 |
| Lease obligations, net of current portion | 6,072 | 6,646 |
| TOTAL LIABILITIES | 276,002 | 146,922 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's total current liabilities?
- ADMA Biologics (ADMA) reported total current liabilities of $75.76M in Q2 2026.
- How has ADMA Biologics's total current liabilities changed year-over-year?
- ADMA Biologics's total current liabilities increased by 1.1% year-over-year, from $74.94M to $75.76M.
- What is the long-term trend for ADMA Biologics's total current liabilities?
- Over 5 years (2020 to 2025), ADMA Biologics's total current liabilities has grown at a 28.4% compound annual growth rate (CAGR), from $19.95M to $69.54M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about ADMA Biologics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude